Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iadademstat - Oryzon Genomics

Next Previous
Drug Profile

Iadademstat - Oryzon Genomics

Alternative Names: ORY 1001; RG 6016; RO-7051790

Latest Information Update: 07 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ministry of Economy and Competitiveness; Oryzon
  • Developer Fox Chase Cancer Center; National Cancer Institute (USA); Oryzon; Roche
  • Class Antianaemics; Antineoplastics; Cyclohexanes; Cyclopropanes; Diamines; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Neuroendocrine tumours; Small cell lung cancer
  • Phase I Myelodysplastic syndromes
  • Preclinical Sickle cell anaemia
  • No development reported Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 30 Jul 2025 Oryzon files a Clinical Trial Application with the EMA in for Sickle cell anaemia before July 2025
  • 30 Jul 2025 Oryzon plans to submit a Clinical Trial Application to the EMA for Essential thrombocythaemia in the second half of 2025
  • 30 Jul 2025 Oryzon plans a clinical trial in Essential thrombocythaemia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top